TABLE III.
SEER 2000 Staging and Treatment per Primary Site of Oral Cavity or Pharyngeal Malignancy.
| Staging SEER 2000 stagea | Buccal Mucosa | Tongue | Lip | ||||||
|---|---|---|---|---|---|---|---|---|---|
| USAPI (51) | US (3633) | USAPI (44) | US (20211) | USAPI30 | US (7812) | ||||
| 1 | 14 (27.5%) | 2061 (56.7%) | 15 (34.1%) | 12902 (63.8%) | 11 (36.7%) | 7247 (92.8%) | |||
| p-valueb | <0.001 | <0.001 | <0.001 | ||||||
| 2 | 9 (17.6%) | 201 (5.5%) | 2 (4.5%) | 859 (4.3%) | 2 (6.67%) | 164 (2.1%) | |||
| p-value | <0.001 | 0.78 | 0.27 | ||||||
| 3 | 2 (3.9%) | 435 (12.0%) | 4 (9.1%) | 3538 (17.5%) | 9 (30.0%) | 217 (2.8%) | |||
| p-value | 0.12 | 0.20 | <0.001 | ||||||
| 4 | 7 (13.1%) | 133 (3.7%) | 14 (31.8%) | 1210 (6.0%) | 8 (26.7%) | 49 (0.6%) | |||
| p-value | <0.001 | <0.001 | <0.001 | ||||||
| 5 | 10 (19.6%) | 0 (0.0%) | 6 (13.6%) | 3 (0.01 %) | 0 | 1 (0.01%) | |||
| p-value | < 0.001 | <0.001 | 0.95 | ||||||
| 7 | 9 (17.6%) | 803 (22.1%) | 3 (6.8%) | 1699 (8.4%) | 0 | 134 (1.7%) | |||
| p-value | 0.55 | 0.91 | 0.99 | ||||||
a
Chi-squared tests for independence were conducted between the US-associated Pacific Island (USAPI) and SEER (US) cohorts.
b
p-values from Chi-squared tests for independence with Yates correction for entries <10 with an α = 0.0028 after Bonferroni correction.